Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis.

导出 OA

翻译打印收藏纠错

作者： Anne,Cauvet ^[1] ; Arthur,Decellas ^[1] ; Christophe,Guignabert ^[2] ; Dominique,Rongvaux-Gaïda ^[3] ; Raphaël,Thuillet ^[4] ; Mina,Ottaviani ^[2] ; Ly,Tu ^[3] ; François,Rieger ^[2] ; Jérôme,Avouac ^[3] ; Yannick,Allanore ^[2]

作者单位： Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, 75014, France. ^[1] UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", INSERM, Hôpital Marie Lannelongue, Le Plessis-Robinson, France. ^[2] Faculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, Le Kremlin-Bicêtre, France. ^[3] MEDSENIC SAS, Strasbourg, France. ^[4] Rheumatology Department, Université de Paris, Cochin Hospital, Paris, France. ^[5] Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, 75014, France. yannick.allanore@inserm.fr. ^[6] Rheumatology Department, Université de Paris, Cochin Hospital, Paris, France. yannick.allanore@inserm.fr. ^[7]

关键词 Arsenic trioxide Pulmonary fibrosis Pulmonary hypertension Systemic sclerosis

主题词人类(Humans);动物(Animals);小鼠(Mice);硬皮病, 系统性(Scleroderma, Systemic);疾病模型, 动物(Disease Models, Animal);硬皮病, 局部性(Scleroderma, Localized)

DOI 10.1186/s13075-023-03143-2

PMID 37700377

发布时间 2023-11-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交